Pharmaceutical formulations with controlled release of the active substance
CA 1298784 C · Owner: Novartis Ag · Inventors: Zuger, Othmar
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Case 100-6717, Abstract of the Disclosure A controlled release formulation for oral administration comprising - an active substance chosen from the group of Pindolol and a 4-(2,1 3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylate ester, - a pharmaceutically acceptable hydrophilic swellable substance and containing optionally a pharmaceutically acceptable inert fatty material in addition. The formulation has an excellent bioavailability and practically no food interaction after administration. 3700/KD/AB
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted April 14, 1992. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended April 14, 2009.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.